Literature DB >> 9724732

Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents.

N Suzuki1, K Del Villar, F Tamanoi.   

Abstract

Farnesyltransferase inhibitors (FTIs) exhibit the remarkable ability to inhibit transformed phenotypes of a variety of human cancer cell lines and to block the growth of cancer cells in a number of animal model systems. In this paper, we report that the addition of FTI to v-K-ras- transformed NRK cells (KNRK) results in dramatic morphological changes. Within 24 h after the addition of FTI, the round morphology of KNRK cells was changed to an elongated (flattened and spread out) morphology resembling those of untransformed NRK cells. No morphological effects were seen when similar concentrations of FTI were added to NRK cells. Phalloidin staining showed that FTI treatment did not restore the disrupted actin cytoskeleton in KNRK cells. In contrast, FTI addition resulted in the appearance of extensive microtubule networks in KNRK cells. The addition of a low concentration (1.2 nM) of vincristine or vinblastine, agents that interfere with microtubule dynamics, blocked the FTI-induced morphological changes in KNRK cells. In contrast, cytochalasin B, which interferes with actin polymerization, did not block the morphological changes. The FTI-induced morphological changes were associated with a decrease in the percentage of cells in S-phase, and the addition of 1.2 nM vincristine did not have additional effects on cell cycle progression. A higher concentration (12 nM) of vincristine caused synergistic effect with FTI to enrich dramatically KNRK cells in G2/M phase. These results suggest that FTI affects cell morphology and that microtubule dynamics are involved in these processes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724732      PMCID: PMC27923          DOI: 10.1073/pnas.95.18.10499

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Identification of a novel human Rho protein with unusual properties: GTPase deficiency and in vivo farnesylation.

Authors:  R Foster; K Q Hu; Y Lu; K M Nolan; J Thissen; J Settleman
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

2.  Post-translational modification of human brain type I inositol-1,4,5-trisphosphate 5-phosphatase by farnesylation.

Authors:  F De Smedt; A Boom; X Pesesse; S N Schiffmann; C Erneux
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

3.  Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells.

Authors:  W R Bishop; R Bond; J Petrin; L Wang; R Patton; R Doll; G Njoroge; J Catino; J Schwartz; W Windsor
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

Review 4.  Protein prenylation: molecular mechanisms and functional consequences.

Authors:  F L Zhang; P J Casey
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

5.  Homozygous codeletion and differential decreased expression of p15INK4b, p16INK4a-alpha and p16INK4a-beta in mouse lung tumor cells.

Authors:  C R Herzog; E V Soloff; A L McDoniels; F L Tyson; A M Malkinson; A Haugen-Strano; R W Wiseman; M W Anderson; M You
Journal:  Oncogene       Date:  1996-11-07       Impact factor: 9.867

6.  A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.

Authors:  L Sepp-Lorenzino; Z Ma; E Rands; N E Kohl; J B Gibbs; A Oliff; N Rosen
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

7.  Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.

Authors:  T Nagasu; K Yoshimatsu; C Rowell; M D Lewis; A M Garcia
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

8.  Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice.

Authors:  N E Kohl; C A Omer; M W Conner; N J Anthony; J P Davide; S J deSolms; E A Giuliani; R P Gomez; S L Graham; K Hamilton
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

9.  Forced expression of tropomyosin 2 or 3 in v-Ki-ras-transformed fibroblasts results in distinct phenotypic effects.

Authors:  M Gimona; J A Kazzaz; D M Helfman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  Binding of 2',3'-cyclic nucleotide 3'-phosphodiesterase to myelin: an in vitro study.

Authors:  D A De Angelis; P E Braun
Journal:  J Neurochem       Date:  1996-06       Impact factor: 5.372

View more
  10 in total

1.  K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells.

Authors:  S Y Song; I M Meszoely; R J Coffey; J A Pietenpol; S D Leach
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  Farnesyltransferase inhibitors reverse taxane resistance.

Authors:  Adam I Marcus; Aurora M O'Brate; Ruben M Buey; Jun Zhou; Shala Thomas; Fadlo R Khuri; Jose Manuel Andreu; Fernando Díaz; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

3.  Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells.

Authors:  N Suzuki; J Urano; F Tamanoi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 4.  Farnesyltransferase inhibitors: potential role in the treatment of cancer.

Authors:  A D Cox
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Oncogenic Ras-induced morphologic change is through MEK/ERK signaling pathway to downregulate Stat3 at a posttranslational level in NIH3T3 cells.

Authors:  Hsuan-Heng Yeh; Chin-Han Wu; Raghavaraju Giri; Ken Kato; Kimitoshi Kohno; Hiroto Izumi; Cheng-Yang Chou; Wu-Chou Su; Hsiao-Sheng Liu
Journal:  Neoplasia       Date:  2008-01       Impact factor: 5.715

6.  The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.

Authors:  Sarah J O'Meara; B Therese Kinsella
Journal:  Biochem J       Date:  2005-02-15       Impact factor: 3.857

7.  Nur77 as a survival factor in tumor necrosis factor signaling.

Authors:  Shinobu Suzuki; Nobutaka Suzuki; Christine Mirtsos; Thomas Horacek; Elizabeth Lye; Seo-Kyu Noh; Alexandra Ho; Denis Bouchard; Tak W Mak; Wen-Chen Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-18       Impact factor: 11.205

8.  Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.

Authors:  Juran Kato-Stankiewicz; Irina Hakimi; Gang Zhi; Jie Zhang; Ilya Serebriiskii; Lea Guo; Hironori Edamatsu; Hiroshi Koide; Sanjay Menon; Robert Eckl; Sukumar Sakamuri; Yingchun Lu; Quin-Zene Chen; Seema Agarwal; William R Baumbach; Erica A Golemis; Fuyuhiko Tamanoi; Vladimir Khazak
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

9.  Chemical inhibition of NAT10 corrects defects of laminopathic cells.

Authors:  Delphine Larrieu; Sébastien Britton; Mukerrem Demir; Raphaël Rodriguez; Stephen P Jackson
Journal:  Science       Date:  2014-05-02       Impact factor: 47.728

10.  Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells.

Authors:  E Zaganjor; J K Osborne; L M Weil; L A Diaz-Martinez; J X Gonzales; S M Singel; J E Larsen; L Girard; J D Minna; M H Cobb
Journal:  Oncogene       Date:  2013-11-18       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.